Ulcerative colitis
Conditions
Interventions
Control group:The placebo of Tiaochang Xiaoyan tablets (4 tablets per time, 4 times a day, orally) and Mesalamine (2 g per time, 2 times a day, orally) were taken continuously for 12 weeks
Experimental group:Tiaochang Xiaoyan tablets (4 tablets per time, 4 times a day, orally) and Mesalamine (2 g per time, 2 times a day, orally) were taken continuously for 12 weeks
Sponsors
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed with mild and moderate active UC; The ages of between 18 and 75; Suitable for Mesalamine treatment; Those who voluntarily participate in this study and have signed the informed consent form, the process of obtaining the informed consent form should be in accordance with ethical principles;
Exclusion criteria
Exclusion criteria: Pregnant or lactating women, or those who plan pregnancy during the study cycle. Patients with Inflammatory bowel disease has serious complications, such as local stenosis, intestinal obstruction, intestinal perforation, etc. Patients with mental disorders and mental retardation. Those who are seriously ill and need urgent treatment. Patients with severe active infections (e.g. tuberculosis, septicemia, cytomegalovirus infection, listeria infection) and opportunistic infections (e.g. progressive multifocal leukoencephalopathy). Patients who are known to be allergic to the drugs and related drug ingredients used in this study. Those who are participating in clinical trials of other drugs or who have participated in other clinical trials within 4 weeks. Patients who were treated with traditional Chinese medicine or proprietary Chinese medicine within 2 weeks, and within the half-life of 5 biological agents (such as Vidrizumab 25.5 days, enalapril 17.5 days, infliximab 50 days, adamumab 70 days, Usmumab 105 days, Skuciyou monoclonal antibody 135 days, etc.). Patients that the researchers believe are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Individual symptom score;Chinese medicine symptom complex score;Relapse rate;Endoscopic response rate and mucosal healing rate; | — |
Countries
China
Contacts
Public ContactZhang Haiyan
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed